CASI Pharmaceuticals, Inc.
CASIF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962738
No open-market purchases or sales by CASI Pharmaceuticals, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17 in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding CASI Pharmaceuticals, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 19 | 18 | −1 |
| Shares | 344.6K | 275.9K | −68.7K (−19.9%) |
| Value | $882.6K | $1.98M | +$1.10M (+124.5%) |
New holders (3)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 12,916 | $93.9K | 0.00% |
| UBS Group AG | 1,222 | $8.75K | 0.00% |
| Simplex Trading, LLC | 53 | $0 | 0.00% |
Sold out (4)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Vanguard Group Inc | 32,365 | $82.9K |
| Qube Research & Technologies Ltd | 328 | $840 |
| Tower Research Capital LLC (TRC) | 327 | $837 |
| Royal Bank of Canada | 18 | $0 |